Kinarus Therapeutics Holding AG
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
Kinarus Therapeutics Holding AG / Key word(s): Half Year Results Ad hoc announcement pursuant to Art. 53 LR
Ā Basel, Switzerland, August 31, 2022 ā Kinarus Therapeutics Holding AG (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today reported results for the six months ended June 30, 2022, and provided a corporate update. Ā Dr. Alexander Bausch, CEO of Kinarus Therapeutics Holding AG, commented: āWe believe we are well positioned to execute on multiple value-creating milestones. As a first of many, our experienced team is working to deliver in Q3 2022 interim results from our KINFAST Phase 2 clinical trial with hospitalized COVID-19 patientsā. Ā āWe continue to explore various financing options to support initiation of our Phase 2 clinical trials in wet AMD and IPF before the end of 2022,ā Dr. Bausch continued, āWe recently signed a financing deal with Yorkville Advisors, which would allow Kinarus to draw down funds opportunistically to finance our clinical development programs and further strengthen our balance sheet.ā Ā Earlier this month Kinarus held and published on its website a webinar on KIN001ās potential to treat COVID-19 (https://ir.kinarus.com/reports-presentations/#presentations). Ā Ā H1 2022 and Subsequent HighlightsĀ
Analysis of Financial Statements for the Six Months Ended June 30, 2022Ā
Interim consolidated income statement (in TCHF)
Ā Interim consolidated balance sheet (in TCHF)
Ā Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team utilizes its knowledge and drug development competencies to in-license and develop mid-stage clinical assets in which they have identified an increased probability of clinical and regulatory success and a rapid path to market. Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone. Ā Contacts
Ā Legal disclaimerTHIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL NOR AN INTIMATION TO SUBMIT A PROPOSAL FOR THE ACQUISITION OF SECURITIES OF KINARUS THERAPEUTICS HOLDING AG. THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN ANY JURISDICTION WHERE IT IS UNLAWFUL TO BE DISTRIBUTED. End of Inside Information |
Latest News
Latest Reports
Upcoming Events
Event Functions
Additional Functions
Webcasts
Event Functions
Additional Functions
24
Aug 22
Kinarus Therapeutics Holding AG
Replay webinar: Kinarus’ new approach to treating COVID-19